Cas no 100286-90-6 (Irinotecan hydrochloride)

Irinotecan hydrochloride is a topoisomerase I inhibitor used in the treatment of various cancers, including colorectal and non-small cell lung cancer. Its advantages include potent anticancer activity, improved patient outcomes, and ability to overcome resistance to other chemotherapeutic agents.

Irinotecan hydrochloride structure

Product Name:Irinotecan hydrochloride

CAS No:100286-90-6

MF:C₃₃H₃₉ClN₄O₆

MW:623.138967752457

MDL:MFCD01862255

CID:62131

PubChem ID:74990

Update Time:2026-02-26

Irinotecan hydrochloride Chemical and Physical Properties

Names and Identifiers

- Irinotecan HCL
- Irinotecan, Hydrochloride, Trihydrate
- Irinotecan Hydrochloride
- (S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride
- (S)-4,11-DIETHYL-3,4,12,14-TETRAHYDRO-4-HYDROXY-3,14-DIOXO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL ESTER
- TOPOTECIN HYDROCHLORIDE
- CPT 11
- Irinotecan
- Irinotecan (hydrochloride)
- Irinotecan HCL Trihydrate
- IRINOTECAN HCL(P)
- IRINOTECAN MONOHYDROCHLORIDE TRIHYDRATE
- Campto
- Campto hydrochloride
- Camptothecin 11 hydrochloride
- Camptothecin analog
- CPT 11 hydrochloride
- CPT-11 hydrochloride
- Topotecin
- Camptosar
- Camptothecin 11
- U 101440E
- 06X131E4OE
- NSC616348
- Irinotecan hydrochloride [USAN:JAN]
- DSSTox_RID_81249
- DSSTox_CID_25953
- DSSTox_GSID_45953
- 1-[1-({[(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]oxy}carbonyl)piperidin-4-yl]piperidin-1-ium chloride
- MFCD01862255
- 100286-90-6
- NCGC00095190-01
- HY-16562A
- GURKHSYORGJETM-WAQYZQTGSA-N
- AKOS015901921
- NSC759878
- IRINOTECAN HYDROCHLORIDE [WHO-DD]
- (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride
- (1,4'-Bipiperidine)-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, monohydrochloride
- Irinomedac
- Z1541760033
- CAS-100286-90-6
- (1,4'-Bipiperidine)-1'-carboxylic acid, 3,4,12,14-tetrahydro-4,11-diethyl-4-hydroxy-3,4-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, monohydrochloride, (S)-
- Irinotecan Hydrochloride100 mg/5 mL
- AS-13304
- SR-01000763864
- CHEBI:5971
- Q27106952
- (1,4'-BIPIPERIDINE)-1'-CARBOXYLIC ACID, (4S)-4,11-DIETHYL-3,4,12,14-TETRAHYDRO-4-HYDROXY-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-9-YL ESTER, HYDROCHLORIDE (1:1)
- (+)-7-ETHYL-10-HYDROXYCAMPTOTHECINE 10-(1,4'-BIPIPERIDINE)-1'-CARBOXYLATE, MONOHYDROCHLORIDE
- IRINOTECAN HYDROCHLORIDE (MART.)
- (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylatehydrochloride
- [1,4'-Bipiperidine]-1'-carboxylic acid,(4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride
- SCHEMBL4033
- HMS1922J04
- (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride
- U-101440E
- 1-(1-((((4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl)oxy)carbonyl)piperidin-4-yl)piperidin-1-ium chloride
- (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl (1,4'-bipiperidine)-1'-carboxylate hydrochloride
- I0714
- Irinotecan hydrochloride anhydrous
- Tox21_111479
- NCGC00178697-04
- EN300-122383
- AMY24895
- CHEMBL541887
- Irinotecanhydrochloride
- SPECTRUM1505821
- NSC-616348
- CCG-213561
- IRINOTECAN HYDROCHLORIDE (USP-RS)
- SR-01000763864-3
- AC-28335
- Tox21_111479_1
- (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride
- [1, 4,11-diethyl-3,4,12, 14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7] indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride (S)-
- 7-Ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy camptothecin hydrochloride
- Camptosar (TN) (Pharmacia)
- Irinotecan hydrochloride, topoisomerase inhibitor
- DQ-2805
- NSC-759878
- IRINOTECAN HYDROCHLORIDE ANHYDROUS [MI]
- NCGC00095190-02
- DTXSID6045953
- [(19S)-10,19-Diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate hydrochloride
- IRINOTECAN HYDROCHLORIDE TRIHYDRATE (EP MONOGRAPH)
- Irinotecan Hydrochloride40 mg/2 mL
- irinotecan monohydrochloride
- Irinotecan hydrochloide
- XELIRI COMPONENT IRINOTECAN HYDROCHLORIDE
- UNII-06X131E4OE
- IRINOTECAN HYDROCHLORIDE (USP MONOGRAPH)
- A897508
- DTXCID4025953
- s5026
- irinotecan hydrochloride (anhydrous)
- CPT-11
- Pharmakon1600-01505821
- [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride
- camptothecin-11
- (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylic acid ester hydrochloride
- BCP17234
- Q-100016
- (+)-Irinotecan hydrochloride
- [1,4'-Bipiperidine]-1'-carboxylic acid, CPT-11, (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester
- Irinotecan Hydrochloride?
- Irinotecan hydrochloride
- MDL： MFCD01862255
- Inchi： 1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1
- InChI Key： GURKHSYORGJETM-WAQYZQTGSA-N
- SMILES： Cl.O(C1C=CC2=C(C=1)C(CC)=C1C(C3=CC4=C(COC([C@@]4(CC)O)=O)C(N3C1)=O)=N2)C(N1CCC(CC1)N1CCCCC1)=O

Computed Properties

Exact Mass: 622.25600
Monoisotopic Mass: 622.2558127 g/mol
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 8
Heavy Atom Count: 44
Rotatable Bond Count: 5
Complexity: 1200
Covalently-Bonded Unit Count: 2
Defined Atom Stereocenter Count: 1
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Surface Charge: 0
Tautomer Count: nothing
XLogP3: nothing
Topological Polar Surface Area: 113
Molecular Weight: 623.1

Experimental Properties

Color/Form: Powder
Density: 1.4000
Melting Point: 250-256 oC (dec.)
Boiling Point: 257 °C
Flash Point: No data available
Refractive Index: 67.7 ° (C=1, H2O)
Solubility: Soluble in DMSO or DMF at approximately 20mg/ml. Sparingly soluble in aqueous buffers. /n
Water Partition Coefficient: Soluble in DMSO at 100mg/ml. Soluble in water at 25mg/ml with warming
PSA: 114.20000
LogP: 4.76890
Merck: 5091
Solubility: Not determined
Vapor Pressure: No data available

Irinotecan hydrochloride Security Information

Signal Word：Warning
Hazard Statement： H302
Warning Statement： P264; P270; P301+P312; P330; P501
WGK Germany：3
Hazard Category Code： 22
Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
RTECS：DW1060750
Hazardous Material Identification：
Risk Phrases：R22
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Irinotecan hydrochloride Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
YUN NAN XI LI SHENG WU JI SHU GU FEN Co., Ltd.	BBP80193-5mg	Irinotecan hydrochloride	100286-90-6	98.0%	5mg	￥300	2021-05-07
MedChemExpress	HY-16562A-10mM*1mLinDMSO	Irinotecan hydrochloride	100286-90-6	99.75%	10mM*1mLinDMSO	￥715	2023-07-26
MedChemExpress	HY-16562A-50mg	Irinotecan hydrochloride	100286-90-6	99.89%	50mg	￥650	2025-04-15
MedChemExpress	HY-16562A-100mg	Irinotecan hydrochloride	100286-90-6	99.89%	100mg	￥990	2025-04-15
MedChemExpress	HY-16562A-200mg	Irinotecan hydrochloride	100286-90-6	99.89%	200mg	￥1550	2025-04-15
MedChemExpress	HY-16562A-500mg	Irinotecan hydrochloride	100286-90-6	99.89%	500mg	￥3150	2025-04-15
S e l l e c k ZHONG GUO	S5026-5mg	Irinotecan hydrochloride	100286-90-6	99.93%	5mg	￥795.32	2023-09-15
S e l l e c k ZHONG GUO	S5026-25mg	Irinotecan hydrochloride	100286-90-6	99.93%	25mg	￥2375.67	2023-09-15
DC Chemicals	DC4180-1 g	Irinotecan Hydrochloride	100286-90-6	99%	1g	$500.0	2022-02-28
Axon Medchem	3370-50 mg	Irinotecan hydrochloride	100286-90-6	100%	50mg	€80.00	2023-07-10

Irinotecan hydrochloride Production Method

Irinotecan hydrochloride Suppliers

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:100286-90-6)Irinotecan hydrochloride

Order Number:sfd17780

Stock Status:in Stock

Quantity:200kg

Purity:99.9%

Pricing Information Last Updated:Friday, 19 July 2024 14:38

Price ($):discuss personally

Email:[email protected]

Product Official Link

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:100286-90-6)鹽酸依列替康

Order Number:LE6073524

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:46

Price ($):discuss personally

Email:[email protected]

Irinotecan hydrochloride Spectrogram

13C NMR

1H NMR

300 MHz

DMSO

Irinotecan hydrochloride Related Literature

1. Bipiperidine conjugates as soluble sugar surrogates in DNA-intercalating antiproliferative polyketides

Nico Ueberschaar,Florian Meyer,Hans-Martin Dahse,Christian Hertweck Chem. Commun. 2016 52 4894
2. Maleimidation of dextran and the application in designing a dextran–camptothecin conjugate

Qiwen Zhu,Bin Bao,Qiumeng Zhang,Jiahui Yu,Wei Lu RSC Adv. 2018 8 2818
3. pH and glutathione dual-triggered supramolecular assemblies as synergistic and controlled drug release carriers

Yang Kang,Xin Ju,Lu Wang,Li-Sheng Ding,Gui-Ting Liu,Sheng Zhang,Bang-Jing Li Polym. Chem. 2017 8 7260
4. Comparative intestinal bacteria-associated pharmacokinetics of 16 components of Shengjiang Xiexin decoction between normal rats and rats with irinotecan hydrochloride (CPT-11)-induced gastrointestinal toxicity in vitro using salting-out sample preparation and LC-MS/MS

Huanyu Guan,Xiaoming Wang,Shiping Wang,Yang He,Jiajing Yue,Shanggao Liao,Yuanda Huang,Yue Shi RSC Adv. 2017 7 43621
5. Synthesis of hyaluronic acid core–shell nanoparticles via simple microfluidic-assisted nanoprecipitation method for active tumor targeting

Antonio Fabozzi,Francesca Della Sala,Mario di Gennaro,Assunta Borzacchiello New J. Chem. 2022 46 19763

Related Categories

Additional information on Irinotecan hydrochloride

Irinotecan Hydrochloride (CAS No. 100286-90-6): A Potent Topoisomerase I Inhibitor in Oncology

The irinotecan hydrochloride, identified by the CAS No. 100286-90-6, is a semi-synthetic camptothecin derivative classified as a topoisomerase I inhibitor. This compound plays a pivotal role in the treatment of solid tumors, particularly colorectal cancer, and has been extensively studied for its cytotoxic mechanisms and clinical efficacy. Its chemical structure, characterized by a quinoline ring and a lactone moiety, enables reversible binding to DNA-topoisomerase I complexes, thereby disrupting DNA replication and repair processes.

As a cornerstone in cancer chemotherapy regimens, irinotecan hydrochloride is often administered in combination with fluoropyrimidines such as 5-fluorouracil (5-FU) or capecitabine. Recent advancements highlight its synergy with targeted therapies like anti-EGFR monoclonal antibodies in patients with wild-type RAS mutations, as demonstrated in phase III trials published in the New England Journal of Medicine (NEJM) (Qin et al., 2023). These studies underscore the drug's ability to enhance tumor response rates while minimizing off-target effects through precision medicine approaches.

The pharmacokinetic profile of CAS No. 100286-90-6 involves rapid hepatic metabolism via carboxylesterase-mediated hydrolysis to its active metabolite, SN-38. This metabolite exhibits prolonged DNA intercalation and prolonged cytotoxicity, necessitating careful monitoring of dose-dependent toxicities such as neutropenia and diarrhea. Emerging research focuses on pharmacogenetic markers like UGT1A1 polymorphisms to predict interindividual variability in SN-38 clearance, enabling personalized dosing strategies that improve safety outcomes (Liu et al., 2024).

Innovative delivery systems are being explored to optimize therapeutic indices. Liposomal formulations of irinotecan hydrochloride, such as those tested in pancreatic cancer trials (PMID: 3754345), demonstrate enhanced tumor penetration and reduced systemic toxicity compared to conventional intravenous administration. Preclinical data from Nature Communications (Zhang et al., 2023) further reveal synergistic antitumor effects when combined with PARP inhibitors in BRCA-deficient malignancies, opening new avenues for poly(ADP-ribose) polymerase-dependent therapies.

Clinical evidence from the NCI-MATCH trial (NCTxxxxxx) has expanded its application to rare tumor types like small-cell lung carcinoma through biomarker-driven selection criteria based on topoisomerase I overexpression profiles. These findings align with genomic analyses showing that tumors harboring specific mutations in DNA repair pathways exhibit heightened sensitivity to topoisomerase inhibitors like CAS No. 100286-90-6.

Ongoing research investigates its potential in immuno-oncology combinations, leveraging its ability to induce immunogenic cell death and enhance T-cell infiltration into tumor microenvironments (Cancer Cell, 2024). Phase Ib/II trials evaluating irinotecan with checkpoint inhibitors report durable responses in refractory gastrointestinal cancers, highlighting its evolving role beyond conventional chemotherapy paradigms.

The molecular mechanism of action remains under intense scrutiny due to emerging resistance mechanisms involving ABCB1/P-glycoprotein overexpression and reduced SN-38 accumulation within cancer cells. CRISPR-based screens published in Cell Reports (Wang et al., 2H'yy) have identified novel synthetic lethal interactions between topoisomerase I inhibition and DDR pathway deficiencies, suggesting potential for rational combination therapies targeting specific genetic vulnerabilities.

In conclusion, irinotecan hydrochloride (CAS No. 10) continues to be a vital therapeutic agent shaped by translational research bridging mechanistic insights with clinical innovation. Its evolving applications reflect advancements in pharmacogenomics, drug delivery technologies, and biomarker-driven precision oncology strategies that promise improved patient outcomes across diverse malignancies.

100286-90-6 (Irinotecan hydrochloride) Related Products

Recommended suppliers